vinflunine,docetaxel,erdafitinib,pembrolizumab
pierre fabre,merck,janssen
['bladder', 'thor trial', 'erdafitinib']
yohann loroit with lba ph3 thor trial. showing os, pfs and orr benefit for erdafitinib (compared to physicians choice chemo) post immunotherapy. same safety profile. #asco23 #targetedtherapy #bladdercancer 
Genitourinary Medical Oncologist @mdandersonnews. #bladdercancer #kidneycancer #prostatecancer. My opinion.